Form 4: RELMADA COO Buys 90,000 Shares

RELMADA Therapeutics' Chief Operating Officer, Paul Edward Kelly, acquired 90,000 shares of common stock at $2.20 per share.

Summary

• Paul Edward Kelly, the Chief Operating Officer and a Director of RELMADA THERAPEUTICS, INC. (RLMD), purchased common stock.
• The transaction occurred on November 5, 2025.
• Mr. Kelly acquired 90,000 shares of common stock.
• The purchase price per share was $2.20.
• Following this transaction, Mr. Kelly beneficially owns a total of 502,295 shares of common stock.

Sentiment

Score: 8

Explanation: The Chief Operating Officer's significant direct purchase of company stock indicates strong insider confidence in the company's future prospects and current valuation, which is generally a positive indicator for investors.

Positives

• A significant purchase of 90,000 shares by the Chief Operating Officer and a Director signals strong insider confidence in the company's future prospects and valuation.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

Insider buying, particularly by a high-ranking executive and director, is often interpreted by the market as a positive signal, suggesting that management believes the company's stock is undervalued or expects positive developments. This can potentially influence investor sentiment within the biotechnology or pharmaceutical industry, where executive confidence is closely watched.

Stakeholder Impact

• Shareholders may view this insider purchase as a positive indicator of management's belief in the company's value and future performance, potentially boosting investor confidence.
• Employees might perceive this as a sign of stability and positive future prospects for the company.

Key Dates

Recommendation

The Chief Operating Officer's direct purchase of a substantial block of shares at $2.20 per share signals strong confidence in the company's valuation and future performance. Such insider buying often precedes positive developments or reflects a belief that the stock is currently undervalued, making it a compelling signal for potential investors.

Keywords

RELMADA Therapeutics, RLMD, Insider Trading, Stock Purchase, Paul Edward Kelly, Form 4, Common Stock, Officer Transaction, Director Transaction